Human pancreatic leiomyosarcoma (PZX-7) growing as a serially transplantable xenograft in immunosuppressed mice

A. Zalatnai, József Bocsi, Tibor Csákány, Tamás Fekete, Jovánka Lásztity

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background. Several human leiomyosarcoma xenografts have been established, but pancreatic smooth muscle sarcomas have never been serially transplanted and investigated. Method. Immunosuppression of CBA/CA mice was achieved by thymectomy, whole-body irradiation, and bone marrow reconstruction. Tumor fragments were subcutaneously implanted from a Grade III pancreatic leiomyosarcoma and serially passaged for more than 24 mo. The xenografted tumors were characterized by morphological, morphometrical, biochemical, and flow cytometric methods. Results. The tumor has retained its characteristic morphology and no further differentiation occurred. The mitotic counts and the amount of the connective tissue all remained constant. The calculated volume doubling time was 11.3 d. Immunohistochemically, the tumor proved to be p53-negative, but the strong expression of the bcl-2 remained as a constant feature throughout successive transplantations. The DNA index and the proliferation indices did not change significantly with the time (mean DI: 1.65, range: 1.561-1.70: mean PI: 17.9%, range: 15.3-20.7%). Lactose dehydrogenase (LDH) isoenzyme electrophoresis evidenced a retained human pattern of the tumor even after 32 mo of transplantations. Conclusion. The first human pancreatic leiomyosarcoma xenograft (PZX-7) growing in immunosuppressed mice is described and characterized.

Original languageEnglish
Pages (from-to)33-41
Number of pages9
JournalInternational Journal of Pancreatology
Volume26
Issue number1
Publication statusPublished - 1999

Fingerprint

Leiomyosarcoma
Heterografts
Neoplasms
Transplantation
Thymectomy
Inbred CBA Mouse
Whole-Body Irradiation
Lactose
Sarcoma
Connective Tissue
Immunosuppression
Isoenzymes
Smooth Muscle
Electrophoresis
Oxidoreductases
Bone Marrow
DNA

Keywords

  • Human tumors
  • Lactate dehydrogenase
  • Leiomyosarcoma
  • Pancreatic neoplasms
  • Xenografts

ASJC Scopus subject areas

  • Gastroenterology
  • Endocrinology
  • Oncology

Cite this

Human pancreatic leiomyosarcoma (PZX-7) growing as a serially transplantable xenograft in immunosuppressed mice. / Zalatnai, A.; Bocsi, József; Csákány, Tibor; Fekete, Tamás; Lásztity, Jovánka.

In: International Journal of Pancreatology, Vol. 26, No. 1, 1999, p. 33-41.

Research output: Contribution to journalArticle

Zalatnai, A. ; Bocsi, József ; Csákány, Tibor ; Fekete, Tamás ; Lásztity, Jovánka. / Human pancreatic leiomyosarcoma (PZX-7) growing as a serially transplantable xenograft in immunosuppressed mice. In: International Journal of Pancreatology. 1999 ; Vol. 26, No. 1. pp. 33-41.
@article{6de8aa1d4ce64aba8633a1485668a0fb,
title = "Human pancreatic leiomyosarcoma (PZX-7) growing as a serially transplantable xenograft in immunosuppressed mice",
abstract = "Background. Several human leiomyosarcoma xenografts have been established, but pancreatic smooth muscle sarcomas have never been serially transplanted and investigated. Method. Immunosuppression of CBA/CA mice was achieved by thymectomy, whole-body irradiation, and bone marrow reconstruction. Tumor fragments were subcutaneously implanted from a Grade III pancreatic leiomyosarcoma and serially passaged for more than 24 mo. The xenografted tumors were characterized by morphological, morphometrical, biochemical, and flow cytometric methods. Results. The tumor has retained its characteristic morphology and no further differentiation occurred. The mitotic counts and the amount of the connective tissue all remained constant. The calculated volume doubling time was 11.3 d. Immunohistochemically, the tumor proved to be p53-negative, but the strong expression of the bcl-2 remained as a constant feature throughout successive transplantations. The DNA index and the proliferation indices did not change significantly with the time (mean DI: 1.65, range: 1.561-1.70: mean PI: 17.9{\%}, range: 15.3-20.7{\%}). Lactose dehydrogenase (LDH) isoenzyme electrophoresis evidenced a retained human pattern of the tumor even after 32 mo of transplantations. Conclusion. The first human pancreatic leiomyosarcoma xenograft (PZX-7) growing in immunosuppressed mice is described and characterized.",
keywords = "Human tumors, Lactate dehydrogenase, Leiomyosarcoma, Pancreatic neoplasms, Xenografts",
author = "A. Zalatnai and J{\'o}zsef Bocsi and Tibor Cs{\'a}k{\'a}ny and Tam{\'a}s Fekete and Jov{\'a}nka L{\'a}sztity",
year = "1999",
language = "English",
volume = "26",
pages = "33--41",
journal = "Journal of Gastrointestinal Cancer",
issn = "1941-6628",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Human pancreatic leiomyosarcoma (PZX-7) growing as a serially transplantable xenograft in immunosuppressed mice

AU - Zalatnai, A.

AU - Bocsi, József

AU - Csákány, Tibor

AU - Fekete, Tamás

AU - Lásztity, Jovánka

PY - 1999

Y1 - 1999

N2 - Background. Several human leiomyosarcoma xenografts have been established, but pancreatic smooth muscle sarcomas have never been serially transplanted and investigated. Method. Immunosuppression of CBA/CA mice was achieved by thymectomy, whole-body irradiation, and bone marrow reconstruction. Tumor fragments were subcutaneously implanted from a Grade III pancreatic leiomyosarcoma and serially passaged for more than 24 mo. The xenografted tumors were characterized by morphological, morphometrical, biochemical, and flow cytometric methods. Results. The tumor has retained its characteristic morphology and no further differentiation occurred. The mitotic counts and the amount of the connective tissue all remained constant. The calculated volume doubling time was 11.3 d. Immunohistochemically, the tumor proved to be p53-negative, but the strong expression of the bcl-2 remained as a constant feature throughout successive transplantations. The DNA index and the proliferation indices did not change significantly with the time (mean DI: 1.65, range: 1.561-1.70: mean PI: 17.9%, range: 15.3-20.7%). Lactose dehydrogenase (LDH) isoenzyme electrophoresis evidenced a retained human pattern of the tumor even after 32 mo of transplantations. Conclusion. The first human pancreatic leiomyosarcoma xenograft (PZX-7) growing in immunosuppressed mice is described and characterized.

AB - Background. Several human leiomyosarcoma xenografts have been established, but pancreatic smooth muscle sarcomas have never been serially transplanted and investigated. Method. Immunosuppression of CBA/CA mice was achieved by thymectomy, whole-body irradiation, and bone marrow reconstruction. Tumor fragments were subcutaneously implanted from a Grade III pancreatic leiomyosarcoma and serially passaged for more than 24 mo. The xenografted tumors were characterized by morphological, morphometrical, biochemical, and flow cytometric methods. Results. The tumor has retained its characteristic morphology and no further differentiation occurred. The mitotic counts and the amount of the connective tissue all remained constant. The calculated volume doubling time was 11.3 d. Immunohistochemically, the tumor proved to be p53-negative, but the strong expression of the bcl-2 remained as a constant feature throughout successive transplantations. The DNA index and the proliferation indices did not change significantly with the time (mean DI: 1.65, range: 1.561-1.70: mean PI: 17.9%, range: 15.3-20.7%). Lactose dehydrogenase (LDH) isoenzyme electrophoresis evidenced a retained human pattern of the tumor even after 32 mo of transplantations. Conclusion. The first human pancreatic leiomyosarcoma xenograft (PZX-7) growing in immunosuppressed mice is described and characterized.

KW - Human tumors

KW - Lactate dehydrogenase

KW - Leiomyosarcoma

KW - Pancreatic neoplasms

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=0032872716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032872716&partnerID=8YFLogxK

M3 - Article

C2 - 10566156

AN - SCOPUS:0032872716

VL - 26

SP - 33

EP - 41

JO - Journal of Gastrointestinal Cancer

JF - Journal of Gastrointestinal Cancer

SN - 1941-6628

IS - 1

ER -